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MEKANISME MOLEKUL AUTOFAGI DAN APOPTOSIS YANG DIARUH
OLEH RAPAMISIN DALAM SEL KARSINOMA PAYU DARA T-47D
ABSTRAK
Autofagi adalah laluan degradasi lisosomal suatu konservasi evolusi yang
mengakibatkan degradasi protein dan seluruh organel,  dengan itu ia memainkan
peranan penting dalam proses homeostatik kitaran semula protein dan organel.
Autofagi adalah mekanisme biologi penting yang membolehkan kemandirian sel dan
mengaruhkan kematian sel-sel yang telah rosak. Terdapat banyak bukti menunjukkan
bahawa autofagi mara ke kematian sel autofagik apabila proses autofagi dirangsang
secara berlebihan. Perkaitan fungsi antara apoptosis (kematian sel jenis I) dan
kematian sel autofagik (kematian sel jenis II) pernah dijelaskan. Walau
bagaimanapun, perkaitan molekul dan keadaan laluan molekul yang menentukan
pilihan di antara autofagi dan apoptosis adalah tidak diketahui buat masa ini.
Autofagi dikawal atur oleh laluan kinase rapamisin manusia (mTOR). Diketahui
bahawa mTOR boleh merencatkan proses autofagi dan seterusnya mendorong
perkembangan tumor. Sebagai satu strategi, rapamisin yang diketahui sebagai
perencat mTOR digunakan sebagai pengaruh autofagi dan 3-metiladenina (3MA)
digunakan sebagai perencat autofagi. Dalam kajian ini, ekspresi gen global yang
sistematik telah dijalankan untuk mengkaji proses autofagi yang diaruh rapamisin
dan kesan rapamisin apabila proses autofagi direncatkan. Kajian ini juga
menunjukkan bahawa rapamisin mampu mengaruh autofagi dalam sel karsinoma
payu dara T-47D. Walau bagaimanapun, apabila autofagi direncat oleh 3MA,
rapamisin menunjukkan kesan apoptosis dalam sel payu dara ini. Pemerhatian ini
disokong sepenuhnya oleh pelbagai kaedah yang meggunakan teknik mikroskop. Di
xxiv
samping itu, rapamisin mempunyai nilai Growth inhibition (GI50), total growth
inhibition (TGI) dan lethal concentration (LC50) yang rendah dalam sel T-47D
apabila proses autofagi direncat oleh 3MA, berbanding dengan sel yang dirawat
hanya dengan rapamisin ataupun 3MA. Keputusan ini menunjukkan bahawa
apoptosis adalah mod kematian sel yang efektif jika dibandingkan dengan kematian
sel autofagi. Ekspresi gen PHLDA1 (pleckstrin homology-like domain, family A,
member 1) ditingkatkan dalam kedua-dua proses autofagi dan apoptosis serta
perencatan gen ini mengurangkan aktiviti kedua-duanya. Keputusan ini menyokong
bahawa PHLDA1 mampu menjadi perantur dan mungkin mengawal atur kedua-dua
laluan autofagi dan apoptosis, dan kedua-dua proses ini boleh menggunakan laluan
atau komponen laluan yang sama. Selain daripada itu, ekspresi gen RICTOR
(rapamycin-insensitive companion of mTOR) ditingkatkan dalam apoptosis dan
perencatan gen ini mampu merencatkan aktiviti apoptosis. Ini menunjukkan bahawa
RICTOR juga memainkan peranan dalam apoptosis yang diaruh oleh rapamisin
dalam sel kanser payu dara T-47D. Sebagai kesimpulan, kajian ini memberi suatu
gambaran baru tentang mekanisme molekul autofagi dan apoptosis yang diaruh
rapamisin dalam sel karsinoma payu dara T-47D dan seterusnya menyumbang
kepada kajian semasa yang meneroka persimpangan di antara laluan autofagi dan
apoptosis. Keputusan kajian ini juga mampu menjadi landasan atau idea dalam
rawatan kanser payu dara, iaitu kemungkinan penggunaan perencat autofagi dan
terapi gen yang menggunakan PHLDA1.
xxv
THE MOLECULAR MECHANISMS OF RAPAMYCIN-INDUCED
AUTOPHAGY AND APOPTOSIS IN T-47D BREAST CARCINOMA CELLS
ABSTRACT
Autophagy is an evolutionarily conserved lysosomal degradation pathway
that leads to degradation of proteins and entire organelles and subsequently plays a
crucial role in the homeostatic process of recycling proteins and organelles.
Autophagy is an important biological mechanism that enables cell survival and to
induce death of damage cells. There is increasing evidence that autophagy progresses
to autophagic cell death when the process is over-stimulated. Functional relationships
have been described between apoptosis (Type I cell death) and autophagic cell death
(Type II cell death). However, the molecular relationships and the circumstances of
which molecular pathways dictate the choice between autophagy and apoptosis are
currently unknown. Autophagy is regulated by the mammalian target of rapamycin
(mTOR) kinase pathway. The mTOR are known to inhibit the autophagy process and
subsequently lead to tumor development. As a strategy, rapamycin, a known
inhibitor of mTOR, was used as an autophagy inducer and 3-methyladenine (3MA)
as a classical inhibitor of autophagy. In the present study, a systematic global gene
expression was investigated in rapamycin-induced autophagy and the effects of
rapamycin when autophagy process is inhibited. The findings have demonstrated that
rapamycin was capable of inducing autophagy in T-47D breast carcinoma cells.
However, when autophagy was inhibited by 3MA, rapamycin appeared to induce
apoptosis in these breast cells. This observation was fully supported by various
methods using appropriate microscopic techniques. Furthermore, rapamycin
produced lower growth inhibition (GI50), total growth inhibition (TGI) and lethal
xxvi
concentration (LC50) values in T-47D cells when the autophagy process was
inhibited by 3MA, compared to cells treated either with rapamycin or 3MA alone,
indicating that apoptosis is an effective mode of cell death compared to autophagic
death. The PHLDA1 (pleckstrin homology-like domain, family A, member 1) gene
was found to be up-regulated in both autophagy and apoptosis and silencing this gene
appeared to reduce both activities. These findings strongly support that PHLDA1
mediates and possibly regulates both autophagy and apoptosis pathways and that
these two processes can utilize common pathways or pathway components. On the
other hand, the RICTOR (rapamycin-insensitive companion of mTOR) gene was
found to be up-regulated in apoptosis and silencing this gene has shown to inhibit
apoptotic activity, indicating that RICTOR may also play a role in rapamycin-
induced apoptosis in T-47D breast cancer cells. In conclusion, this study provides
novel insights into the molecular mechanisms of rapamycin-induced autophagy and
apoptosis in T-47D breast carcinoma cells and will definitely make contribution to
the currents studies which explore the intersections between both autophagy and
apoptosis pathways. The results of this study may also open up avenues to explore or
ideas in the treatment of breast cancer, namely the possible utilization of autophagy
inhibitors and gene therapy using PHLDA1.
1CHAPTER 1
INTRODUCTION
21.1 Breast Cancer
Cancer is one of the leading causes of death worldwide, especially in the
economically developing world. According to the Globocan 20081, there were
approximately 12.7 million cancer cases and 7.6 million cancer deaths worldwide in
2008 (Jemal et al, 2011). In 2010, a total of 1,529,560 new cancer cases and 569,490
deaths from cancer were reported to occur in the United States (Jemal et al, 2010).
Breast cancer is the most commonly diagnosed malignancy among women, and the
second only to lung cancer as a cause of cancer deaths in women worldwide (Jemal
et al, 2010). In the past decade, the worldwide incidence of breast cancer has
significant geographical difference; it is highest in developed countries in northern
Europe and North American, intermediate in Mediterranean countries and South
America, and lowest in Asia and Africa (Ferlay et al, 2001). The incidence and
mortality rates of breast cancer has remained higher in developed countries compared
to developing countries (Althuis et al, 2005). Recently, there is a massive increase in
the annual incidence of breast cancer among the countries where its incidence was
low, especially in the Asian countries (Baig et al, 2011; Parkin et al, 2005; Pathy et
al, 2011). The proposed contributing factors to the increase include changes in
reproductive factors, environmental exposures, and differences in lifestyle such as
dietary and physical activity (Hisham and Yip, 2004; Pathy et al, 2011).
In 2000, there were 1.05 million cases of breast cancer reported worldwide,
with 372,969 deaths (Ferlay et al, 2001). In 2002, the number increased to 1.15
million cases, and it is the most prevalent cancer in the world (Parkin et al, 2005).
Among Malaysian women, breast cancer is the most frequent cause of death (Hisham
and Yip, 2004; Lim and Halimah, 2003). In 2003, there were 3,738 female breast
1 Globocan is a unique software program which provides access to information on the incidence and
prevalence of, and mortality from 26 major cancers for all the countries in the world
(http://apps.who.int/bookorders/anglais/detart1.jsp?sesslan=1&codlan=1&codcol=76&codcch=12).
3cancer cases that were reported, making it the most commonly diagnosed cancer in
Malaysian women (Lim and Halimah, 2003). In the year 2006, there were 3,525
female breast cancer cases registered with the National Cancer Registry (NCR) of
Malaysia, accounted for 16.5% of all cancer cases registered (Omar et al, 2006).
Generally, the Age Standardised Rate (ASR) of female breast cancer was 47.4 per
100,000 Malaysian women (Baig et al, 2011).
There are many risk factors associated with development of breast cancer, for
example: sex, age, lack of childbearing or breastfeeding, higher hormone levels, the
long-term use of hormone replacement therapy (HRT), race, economic status, a high-
fat diet, alcohol intake, radiation and dietary iodine deficiency (2002; Aceves et al,
2005; Boffetta et al, 2006; Chen et al, 2002; Chlebowski et al, 2006; Giordano et al,
2004; Stoddard et al, 2008; Venturi, 2001; Yager and Davidson, 2006). Moreover,
the family history of women with a first-degree relative with breast cancer has a risk
two to three times. The risk factor further increases if the relative was affected at an
early age and/or had bilateral disease (Skolnick and Cannon-Albright, 1992).
Recently, smoking tobacco may increase the risk of breast cancer with the greater the
amount of smoking and the earlier in life smoking commences the higher the risk
(Xue et al, 2011).
In addition to the risk factors mentioned above, at the genetic levels, some
oncogenes such as HER-2 (human epidermal growth factor receptor 2); also known
as proto-oncogene Neu, or erb-B (erythroblastic leukemia viral oncogenes homolog
2), c-myc and B-cell lymphoma 2 (Bcl-2); and some tumor suppressor genes
including multiple tumor suppressor 1 (MTS1; known as p16), retinoblastoma (RB),
p53, breast cancer susceptibility gene 1 (BRCA1) and breast cancer susceptibility
gene 2 (BRCA2) are involved in breast cancer (Weinberg, 1996). Approximately, up
4to 10% of breast cancer is hereditary (Carroll et al, 2008). Most women who have
breast cancer do not have the genes associated with hereditary breast-ovarian cancer
syndromes (HBOC); the exception is women and men who are carriers of BRCA1
and BRCA2 mutations. Mutation in either of BRCA1 and BRCA2 genes gives a
woman an increased lifetime risk of developing breast cancers of between 60 and
85% (Wooster and Weber, 2003). In particular, carriers of the BRCA1 and BRCA2
genes are at a 30-40% increased risk for breast cancer, depending on in which
portion of the protein the mutation occurs (Venkitaraman, 2002). Inherited mutations
in BRCA1 and BRCA2 genes are associated with a high risk of developing breast
cancers in women of different age and ethnic groups (de Jong et al, 2002; Farooq et
al, 2011). Although most of BRCA1 and BRCA2 studies have been focused on the
Caucasian populations, the allelic frequency of higher penetrance2 genes in Asian
population may be higher than in Caucasian population (Farooq et al, 2011; Toh et
al, 2008). Other mutations that lead to breast cancer have been experimentally
associated with estrogen exposure (Cavalieri et al, 2006).
Breast cancers have shown loss of heterozygosity (LOH) at one or more of a
large number of chromosomal loci, including 1q, 3p, 6q, 16q, 17p, and 18q in 50% or
more tumors and at 1p, 7q, 8q, 9q, 11p, 13q, 15q, 17q, and 22q in about 30% of
tumors (Callahan and Campbell, 1989; Coles et al, 1992; Cropp et al, 1990). These
findings suggest that the mutations of a number of tumor suppressor genes and
oncogenes are implicated in breast cancer (Callahan and Campbell, 1989). These
mutations are either inherited or acquired after birth, which allow uncontrolled
division of cells, lack of attachment and metastasis to distant organs (Dunning et al,
1999).
2 Penetrance is the likelihood a given gene will result in disease. For example, if half (50%) of the
people with the neurofibromatosis (NF) gene have the disease NF, the penetrance of the NF gene is
0.5 [Dictionary of Medicine].
5Breast epithelial cells, like other normal cells, require the balance of cell
proliferation with a type of cell death called apoptosis which occurs in healthy breast
cells at varying rates in response to changes in both extrinsic and intrinsic pathways
(Wu, 1996). The breast normal cells are protected from apoptosis by several protein
clusters and pathways. One of the protective pathways is PI3K/Akt pathway
(Simstein et al, 2003). Alterations in the genetics of apoptosis mechanisms may
result in an increase in cell numbers, subsequently preservation of genetically altered
cells, leading to the process of tumorigenesis (Furth, 1999). Another programmed
cell death, called autophagy, has a wide involvement in metabolic equilibrium and
homeostasis, makes it an important target in human cancers (Liang and Jung, 2010).
The first association between autophagy and breast cancer was made on the basis of
observations that dysregulation of Beclin-1 expression induces autophagy and
subsequently suppresses breast cancer tumor cell growth (Liang et al, 1999).
Inactivation of autophagy-specific genes, such as Beclin-1, results in increased
tumorigenesis in mice, and compel expression of this gene inhibits the formation of
human breast cancers in mouse models (Levine, 2007).
The breast cancer cell lines have become major experimental models, not
only for breast cancer research but for dissecting basic molecular mechanisms
controlling diverse aspects of epithelial cell biology (Sutherland et al, 1999). The
human breast carcinoma cell line T-47D and two other breast cancer cell lines,
namely MCF-7 and MDA-MB-231, account for more than two-thirds of all reporting
studies on mentioned breast cancer cell lines, as recorded in a Medline-based survey
(Lacroix and Leclercq, 2004). The T-47D cell line was isolated from a pleural
effusion of a 54 year old female patient with an infiltrating ductal carcinoma of the
breast (Keydar et al, 1979). In the two last decades, many studies have shown some
6of the features of T-47D breast cancer cells, focusing on expression of nuclear and
cell surface receptors, signal transduction molecules and cell cycle regulatory
molecules, since these are components of known oncogenic pathways in breast
cancer (Daly et al, 1994; deFazio et al, 1997; Douglas et al, 1997; Hall et al, 1990;
Musgrove et al, 1995; Roman et al, 1992). Furthermore, the usefulness of the T-47D
breast cancer cells as an investigative tool led to its adoption in autophagy and
apoptosis related-studies (Ait-Mohamed et al, 2011; Bruning et al, 2010;
Mathivadhani et al, 2007; Mooney et al, 2002).
1.2 Programmed Cell Death (PCD)
Cell death refers to any form of death of a cell mediated by intracellular death
process (Engelberg-Kulka et al, 2006). The process of cell death in multicellular
organisms has been documented many times during the past 150 years (Peter et al,
1997; Vaux, 2002). Since the first description of the term “programmed cell death”,
which date back to 1964, many attempts have been made to classify cell death
categories based on morphological characteristics (Galluzzi et al, 2012b; Lockshin
and Williams, 1964). Thus, in 1973 it has proposed a classification of cell death
modalities, including cell death type I (apoptosis), cell death type II (autophagic cell
death), and cell death type III (necrosis), depending on the morphological and
biochemical features (Clarke, 2002; Gozuacik and Kimchi, 2007; Kroemer et al,
2005; Schweichel and Merker, 1973). The molecular pathways that mediate cell
death have been investigated and the biochemical assays for monitoring cell death
have become laboratory routine. A systematic classification of cell death categories
based on biochemical rather than morphological characteristics has got to be adopted
(Galluzzi et al, 2012b).
7The Nomenclature Committee on Cell Death (NCCD) 2012 has
recommended appropriate use of cell death-related terminology, including extrinsic
apoptosis, caspase-dependent or -independent intrinsic apoptosis, autophagic cell
death, regulated necrosis and mitotic catastrophe. According to the NCCD, extrinsic
apoptosis refers to instances of apoptotic cell death that are induced by extracellular
stress signals that are stimulated by specific transmembrane receptors. However,
intrinsic apoptosis can be triggered by intracellular stress conditions; such as DNA
damage and oxidative stress, leading to cell death process that is mediated by
mitochondrial outer membrane permeabilization (MOMP) (Galluzzi et al, 2012b).
The term “autophagic cell death” has been used to indicate instances of cell death
that are accompanied by a massive cytoplasmic vacuolization, which indicates
increased autophagy process that can be suppressed by the inhibition of the
autophagic pathway (Galluzzi et al, 2012b).
Furthermore, NCCD proposed recommendations for the suitable use of cell
death-related terminology, including programmed cell death, for the physiological
instances of cell death that occur in the context of embryonic development and tissue
homeostasis; regulated cell death; for cell death that occurs in the molecular
mechanisms mediating like inhibition by targeted pharmacological and/or genetic
interventions; and accidental cell death; for cell death that triggered by extremely
harsh physical conditions like freeze-thawing cycles (Galluzzi et al, 2012b).
Autophagy and apoptosis are very important physiological mechanisms that
control the development, homeostasis, and elimination of unwanted and malignant
cells (Hockenbery et al, 1990; Wang and Klionsky, 2003). Apoptosis can start with
autophagy, autophagy can end with apoptosis, and obstruction of caspase activity can
cause a cell to default from apoptosis to autophagy (Lockshin and Zakeri, 2004). The
8relationship between autophagy and apoptosis is varied and complex. These two
pathways can be almost linked by specific molecular triggers, either in a positive,
regulated manner which balances cell proliferation, or in a negative, unregulated
manner which results in tumor formation (Gozuacik and Kimchi, 2004).
1.3 Apoptosis
The term “apoptosis” is derived from the Greek word used to describe the
“falling off leaves from a tree” (Malcolm, 2007). The chronological history of
apoptosis is described in Table 1.1 (Vaux, 2002). Apoptosis is a mode of cell death
that occurs in response to cytotoxic compounds, cell dysfunction and infection. This
cellular process can be initiated by either extrinsic or intrinsic stimuli. It is of
fundamental importance in the development, growth, health and tissue homeostasis
of multicellular organisms (Dunn et al, 2007).
Apoptosis is defined by biochemical events, including activation of
intracellular proteases and internucleosomal DNA fragmentation, leading to
morphological changes including cell membrane blebbing, cell shrinkage and
chromatin condensation that characterized cell death (Kerr et al, 1972). Apoptosis in
mammalian cells is mediated by a family of cysteine proteases known as caspases
(Alnemri et al, 1996).
The molecular events of apoptosis can be divided into three steps: initiation
by an apoptosis-inducing agent, activation of the caspases by a signal transduction
cascade, and proteolytic cleavage of cellular components (Simstein et al, 2003). In
apoptosis, there are many death and survival genes which are regulated by
extracellular factors. The initial steps of apoptosis occurs in the membrane during
9Table 1.1 Timeline, a history of apoptosis
Year Event
1842
The cell death occurring normally during vertebrate development was
recognized (Vaux, 2002).
1951
The first examination of cell death as a normal part of vertebrate development
was described (Glucksmann, 1951).
1961
The developmental cell death was featured by transmission electron
microscope (Bellairs, 1961).
1966
The cell death was found to be active process through linking of
developmental and hormonally regulated cell death (Tata, 1966)
1972
The term “Apoptosis” was used to describe vertebrate cell deaths (Kerr et al,
1972).
1980
Chromatin condensation and DNA degradation were discovered as some
characters of apoptosis (Wyllie, 1980).
1985
Targets of cytotoxic T cells (CTL) killing was displayed the characteristic
features of apoptosis (Clouston and Kerr, 1985).
1986
Withdrawal of growth factor found to activate apoptosis (Duke and Cohen,
1986).
First cell death gene (ced-3), now known as caspase-8, which is essential for
apoptosis in the worm was recognized (Ellis and Horvitz, 1986).
1988
The Bcle-2 was discovered as the first identification of component of the
apoptosis mechanism (Vaux et al, 1988).
1989
Fas/Apo-1 (CD95) was known to signal apoptosis when crosslinked by
antibodies (Trauth et al, 1989; Yonehara et al, 1989).
1991
P53 was found to cause apoptosis via the mechanism that can be blocked by
Bcl-2 (Chiou et al, 1994; Yonish-Rouach et al, 1991).
1993
Bax, a Bcl-2 family member, was promoted caspase activity (Oltvai et al,
1993).
1994
The first inhibitor of apoptosis (IAP) gene, p35, was identified in
baculoviruses (Birnbaum et al, 1994).
1995
Several mammalian IAP genes have been discovered (Roy et al, 1995; Uren et
al, 1996).
1996
Increased release cytochrome c to cytosol was suggested that mitochondria
may function in apoptosis by releasing cytochrome c (Liu et al, 1996).
1997
Apaf-1 and caspase-9 were identified in human (Li et al, 1997b; Zou et al,
1997).
Cytochrome c was revealed to be a molecule capable of activating Apaf-1
(Liu et al, 1996).
1998
Apoptosis was found to mediate by death receptors belong to TNF receptor
superfamily in the extrinsic pathway (Schulze-Osthoff et al, 1998).
Bax was found to increase the membrane’s permeability and initiate the
caspase pathway for apoptosis (Marzo et al, 1998; Narita et al, 1998).
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Table 1.1 Continued
Year Event
1999
Bak was found to be a proapoptotic membrane of the Bcl-2 family (Gross et
al, 1999).
2000
Smac/Diablo, the second protein in the apoptosis link, along with cytochrome
c, that promotes apoptosis by activating caspases, was identified as inhibitors
of mammalian IAPs (Du et al, 2000; Verhagen et al, 2000).
2001
Smac/Diablo was found to displace caspase-9 from IAPs (Srinivasula et al,
2001).
2003
Phagocytes lacking the phosphatidylserine receptor (PSR) were found to be
defective in removing apoptotic cells (Li et al, 2003).
The cytotoxic T lymphocytes (CTLs) were found to be able to kill target cells
via the extrinsic pathway, and FasL/FasR interaction was found to be the
predominant method of CTL-induced apoptosis (Brunner et al, 2003)
2007
Golgi-anti-apoptotic protein (GAAP), a new regulator of apoptosis, was
described to be expressed in all human tissues tested, inhibited apoptosis
induced by intrinsic and extrinsic apoptotic stimuli (Gubser et al, 2007).
The first parapoxvirus apoptosis inhibitor, ORFV125, is identified as a new
antiapoptotic member of the Bcl-2 family (Westphal et al, 2007).
2009
B-cell lymphoma 2 interacting mediator of cell death (BIM) is a new mediator
of tumor cell death, either apoptosis or autophagy, in response to novel
oncogene-targeted therapeutics (Gillings et al, 2009).
2010
Overexpression of a pro-apoptotic Par-4 protein was found to sensitize
TRAIL-induced apoptosis via inactivation of NF-kappaB and Akt signaling
pathways (Lee et al, 2010)
2011 Par-4 was found to be a novel specific caspase-3 cleavage site, and thecleaved fragment of Par-4 retains proapoptotic activity (Chaudhry et al, 2012).
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ceramide generation through activation of sphingomyelinase (SMase) and
downstream signaling involving Bcl-2 family members, the inhibitor of apoptosis
(IAP) family of proteins, the transcription factor nuclear factor-κB (NF-κB),
members of the mitogen-activated protein kinase (MAPK) family, such as
p42/44MAPKs (extracellular signal-related kinases [ERKs]), SAPK/JNK, and
p38MAPK, and caspases (Baldwin, 2001; Ballif and Blenis, 2001; Deveraux and
Reed, 1999; Fadeel et al, 1999; Kaufmann and Earnshaw, 2000; Liu et al, 1999;
Reed, 2001). Apoptosis process is determined by the balance between pro-apoptotic
and anti-apoptotic regulators expressed in the cells (Simstein et al, 2003).
The family of mammalian apoptotic proteases, which are known as caspases,
are classified as activator (initiator) caspase (e.g. caspases-2, -8, -9, -10 and -12),
which cleave and activate downstream effector caspases, or executioner (effector)
caspases (e. g. caspases-3, -6, and -7), which cleave various cellular proteins
substrates within the cell, to trigger the apoptosis pathway (Earnshaw et al, 1999;
Fan et al, 2005). The initiator caspases (such as caspase-2, -8, -9, and -10) are
activated by formation three of caspase-activating complexes including: DISC
(Death Inducing Signaling Complex), which activates caspases-8 and 10;
Apoptosome, which activates caspase-9; and PIDDosome, which activates caspase-2
(Park, 2012). There are two known pathways that activate the caspases cascade; the
extrinsic pathway, which is independent of mitochondria and is induced by death
receptor-protein complexes that cleave procaspase-8, and the intrinsic pathway,
which involves the Bcl-2 family of proteins and the release of cytochrome c from
mitochondria (Figure 1.1) (Gross et al, 1999; Simstein et al, 2003).
The extrinsic apoptosis signaling pathway is mediated by the activation of
death receptors, which belong to the tumor necrosis factor receptor (TNFR) gene
12
Figure 1.1 The intrinsic and extrinsic apoptotic pathways.
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family such as TNFR-1, Fas/CD95, and the TRAIL receptors DR-4 and DR-5
(Ashkenazi, 2002). Ligands, including TNF ligands, TNF ligand superfamily
member 10 (TNFSF10), Fas ligand and TRAIL (TNF-related apoptosis-inducing
ligand), interact with their specific death receptors, recruiting Fas-associated death
domain adapter protein (FADD) and thereby forming the death inducing signaling
complex (DISC) (Sartorius et al, 2001). This complex mediates activation of pro-
caspase-8 and pro-caspase-10, leading to the activation of the executioner caspases-
3, -6, and -7 which in turn cleave a number of protein substrates (Hengartner, 2000;
Schulze-Osthoff et al, 1998). Active caspase-3 or caspase-7 eventually leads to the
characteristic morphological and biochemical features of apoptosis. Both caspase-3
and -7 cleaves DNA fragmentation factor 45 (DFF45) which subsequently releases
active DFF40; the inhibitor’s associated endonuclease, which is responsible for the
degradation of chromosomes into nucleosomal fragments (Widlak and Garrard,
2005; Wolf et al, 1999).
The intrinsic apoptosis signaling pathway is mediated by mitochondria
through release of cytochrome c and Smac (second mitochondria-derived activator of
caspases)/Diablo (direct inhibitor of apoptosis-binding protein) from the
mitochondrial intermembrane space to the cytosol, responding to apoptotic stimuli
including DNA damage, γ-irradiation, and serum deprivation (Gross et al, 1999;
Hengartner, 2000). DNA damage induces the expression of PIDD (p53-induced
protein with death domain) which binds to the adaptor protein RAIDD (receptor
interacting protein (RIP)-associated Ich-1/Ced-3 homologous protein with a death
domain) and precaspase-2 forming the PIDDosome and leads to the activation of
caspase-2 (Jang et al, 2010a; Jang et al, 2010b). Caspase-2 is involved in Bid cleaved
and Bax translocation, which results in cytochrome c release during DNA damage
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(Bouchier-Hayes, 2010; Lassus et al, 2002; Tinel and Tschopp, 2004). Cytochrome c
contributes to the formation of the apoptosome which consists of cytochrome c,
apoptotic protease activating factor-1 (Apaf-1) and dATP. Subsequently, the
apoptosome recruits the initiator pro-caspase-9, leading to the activation of caspase-9
which finally mediates the activation of caspase-3 and caspase-7 (Denault and
Salvesen, 2002; Earnshaw et al, 1999). Smac, another mitochondrial proapoptotic
factor, acts by inhibiting the inhibitors of apoptosis (IAPs) from blocking caspase
activity. IAPs are a family of proteins with antiapoptotic activity by directly
inhibiting caspases. Currently, eight human IAPs have been identified such as X-
linked IAP (XIAP), IAP-like protein-2 (IAP-2), cellular inhibitor of apoptosis-1 and
2 (c-IAP-1 and c-IAP-2), melanoma inhibitor of apoptosis protein (MLIAP),
neuronal apoptosis inhibitory protein (NAIP), survivin and apollon (Salvesen and
Duckett, 2002). XIAPs and c-IAP1/2 block cytochrome c-induced activation of
caspase-9, thus preventing the activation of caspase-3, -6 and -7. In addition, they
bind to and inhibit the enzymatic activity of caspase-3 leading to blocking
downstream apoptotic events by the initiator caspase (Deveraux et al, 1998).
The B-cell lymphoma 2 (Bcl-2) family members play an important role in the
regulation of mitochondrial-linked apoptosis (Tsujimoto, 1989). Activated
proapoptotic Bcl-2 subfamilies such as Bax and Bak form homo-oligomer which
creates pores on the mitochondrial membrane and subsequent release cytochrome c
from the mitochondria. Cytochrome c binds to and activates Apaf-1 protein in the
cytoplasm leading to the formation of apoptosome (Hengartner, 2000) The
antiapoptotic Bcl-2 family members such as Bcl-2 and Bcl-xL which counteract the
action of proapoptotic Bcl-2 subfamilies such as Bax, Bak, and Bcl-2 homolog
(BH)3-only family (e.g. Bid) and therefore can inhibit mitochondrial proapoptotic
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events (Tsujimoto, 1998). The intrinsic apoptotic signals coming from the inside of
the cell frequently have their origin within the nucleus, being a consequence of DNA
damage, which in most cases results in the activation of the p53 transcription factor
which stimulates expression of proapoptotic Bcl-2 members and represses
antiapoptotic Bcl-2 and Bcl-xL (Hoffman et al, 2002; Wu et al, 2001).
Interestingly, in addition to mitochondria and the nucleus, the endothelium
reticulum and lysosomes also have been implicated in apoptotic pathways and
seemingly hundreds of proteins are part of an extremely fine-tuned regulatory
network consisting of pro- and antiapoptotic factors (Gewies, 2003).
Apoptosis is a very important developmental pathway which serves as a
defense mechanism to remove unwanted and potentially dangerous cells that have
been infected by virus and cancer cells. However, it is important to mention that the
inappropriate activation of apoptosis may contribute to the pathogenesis of many
diseases such as cancer, neurodegenerative disorders, autoimmune disease, acquired
immunodeficiency syndrome and resistance to chemotherapy (Vinatier et al, 1996).
Therefore, different attempts are being directed towards identifying the
crucial steps in the apoptosis process, the main purpose being to design therapeutic
approaches that control cell death by altering (stimulating or inhibiting) signaling
molecules in the pathway. Methods to quantify apoptosis and to distinguish it from
necrosis have been developed3. The explosion of interest in apoptosis and cell death
studies has resulted in the development of a diversity of different apoptosis detection
methods. There are a wide variety of new techniques available, but each technique
has its advantages and disadvantages which may make it acceptable to use for one
3 Necrosis refers to the morphology usually associated with accidental cell death which occurs when
cells are exposed to a serious physical or chemical insult, while apoptosis is seen when cell death is
programmed or physiologically regulated (Martin D, Lenardo M (2001). Morphological, biochemical,
and flow cytometric assays of apoptosis. Curr Protoc Mol Biol Chapter 14: Unit 14 13.)
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application but not suitable for another application (Watanabe et al, 2002).
Historically, the study of apoptosis was first based on cell morphology using
transmission electron microscopy (TEM): chromatin condensation, cellular
shrinkage, break-up of the cell and its engulfment (Bellairs, 1961). Several
approaches have been used, including appearance of the characteristic 180 base pairs
DNA ladder banding pattern on agarose gels (Wyllie, 1980). Subsequently, marked
progress in biochemistry, molecular biology and genetics provided researchers
various methods for apoptosis detection, such as the TUNEL (TdT-mediated dUTP
Nick-End Labeling) assay, flow cytometry, DNA fragmentation ELISA (Ito et al,
1996; Kressel and Groscurth, 1994; Salgame et al, 1997). Subsequently, the caspase
family of proteases has been identified as common mediators of the cell suicide
pathway that can be detected using various types of caspase activity assays (Gurtu et
al, 1997). Caspase activation can be detected in different ways including western blot
and immunohistochemistry (Elmore, 2007; Talasz et al, 2002). Some of these assay
systems have been described as measuring the early stages of apoptosis when the
pro-apoptotic stimuli trigger activation of the molecular machinery of apoptosis,
leading the molecular executioner machinery becomes totally activated as shown by
the ability of the cytosolic extracts of cells to induce apoptotic changes in nuclei
(Lazebnik et al, 1993; Solary et al, 1993). On the other hand, some assays systems
have been described as measuring the late stages in the overall process of apoptosis
when the hallmarks of apoptosis become evident including morphologic changes and
DNA fragmentation (Saraste and Pulkki, 2000). Since much remains incompletely
understood about the molecular pathways of apoptosis, and it is probably best to
carry out more than one of the basic techniques to confirm an investigation of
apoptotic cells (Muppidi et al, 2004a).
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1.4 Autophagy
Two primary intracellular protein degradation pathways are known in
eukaryotic cells: the ubiquitin-proteasome system (UPS) and the lysosome (Figure
1.2) (Luo et al, 2010). The differences between these two major protein degradation
systems depend on their functional significance and the type of substrates they take
in for degradation (Gao et al, 2009). In the proteasome system, the UPS catalyses the
rapid degradation of abnormal proteins and short-lived regulatory proteins leading to
control a diversity of essential cellular processes (Ciechanover, 1998). In the
lysosomal protein degradation pathway, the degradation of extracellular materials is
mediated by endocytosis, whereas the degradation of intracellular long-time
cytoplasmic proteins and damaged organelles is mediated by three types of
autophagy: macroautophagy, microautophagy and chaperone-mediated autophagy
(CMA), which are classified based on their transport of cytoplasmic materials into
the lysosome for degradation (de Duve and Wattiaux, 1966; Gao et al, 2009; Meijer
and Codogno, 2004).
The term autophagy literally comes from Greek, meaning “self-eating” (Gao
et al, 2009; Liu et al, 2010a; Tan et al, 2009). Interestingly, although autophagy was
first described more than 50 years ago, the molecular understanding of it has just
started in the past decade. The chronological history of autophagy research is
described in Table 1.2 (Klionsky, 2007). In the year 1957, Clark observed a process
of bulk segregation of mitochondria within membrane-bounded compartments
termed “dense bodies”, which were subsequently shown to include lysosomal
enzymes (Clark, 1957). The same bodies containing the cellular components and
lysosomal hydrolases was observed and reported between the years 1959 and 1962
(Ashford and Porter, 1962; Novikoff, 1959; Novikoff and Essner, 1962). One year
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Figure 1.2 The autophagy pathway is one of essential primary intracellular
protein degradation systems in eukaryotes (Luo et al, 2010).
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Table 1.2 Timeline, a history of autophagy
Year Event
1955 The lysosome was described (de Duve et al, 1955).
1963 The morphological process was described, and the name “autophagy” was coined.
1967 Glucagon was found to induce autophagy (Deter et al, 1967).
1973
The selective sequestration of an organelle was demonstrated (Bolender and Weibel,
1973).
1977
Amino acids were found to inhibit autophagy (Mortimore and Schworer, 1977).
The autophagy function was suggested as a cell-death mechanism (Beaulaton and
Lockshin, 1977).
1982
The first biochemical analysis of autophagy was carried out, and 3-methyladenine
(3MA) was identified as an inhibitor (Caro et al, 1988; Gordon and Seglen, 1982;
Seglen and Gordon, 1982).
1988
The amphisome was identified as a convergence point between autophagy and
endocytosis (Gordon and Seglen, 1988).
1992 The morphology of autophagy was showed in yeast (Takeshige et al, 1992)
1993
The first screen was reported to identify yeast autophagy mutants (Tsukada and
Ohsumi, 1993).
Different methods were used to isolate autophagy mutants (Klionsky et al, 2003).
1995 The stimulatory role of rapamycin was documented (Blommaart et al, 1995).
1997
A stimulatory role for PI3K was found (Blommaart et al, 1997).
The yeast Atg1 was cloned (Matsuura et al, 1997)
Thirty more Atg genes were identified in yeasts (Kabeya et al, 2007; Kawamata et al,
2005; Klionsky et al, 2003; Stasyk et al, 2006).
1998
The first mammalian autophagy gene was identified, and the conservation of Atg12-
Atg5 conjugation was shown (Mizushima et al, 1998).
1999
BECN1/Atg6 was identified as a Bcl2-interacting protein and tumor suppressor
(Liang et al, 1999).
2000
LC3 assays were developed for monitoring autophagy in higher leukaryotes (Kabeya
et al, 2000).
2002
The protective role of autophagy was shown in Huntington’s disease (Ravikumar et
al, 2002)
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Table 1.2 Continued
Year Event
2003
Deficient autophagy was found to contribute of tumorigenesis in vivo (Qu et al, 2003;
Yue et al, 2003).
The relationship between autophagy and longevity was identified (Bergamini, 2006;
Melendez et al, 2003).
2004
The evidence of a physiological role for autophagy in neonatal mice was provided
(Kuma et al, 2004).
The evidence of a role for autophagy in innate and adaptive immunity was provided
(Dengjel et al, 2005; Gutierrez et al, 2004; Liu et al, 2005).
The cell death was shown to depend on autophagy proteins (Clarke et al, 2009;
Shimizu et al, 2004; Yu et al, 2004).
First crystal structure of autophagy protein was determined (Sugawara et al, 2004).
2006
The role for basal autophagy in preventing neurodegeneration was demonstrated
(Hara et al, 2006; Komatsu et al, 2006).
2008
The relationship between mTOR-independent pathways and autophagy was
uncovered (Wei et al, 2008)
2009
The mitochondria-anchored receptor Atg32 was identified as a mediator in
degradation mitochondria via selective autophagy (Okamoto et al, 2009).
2010
The endoplasmic reticulum membrane, the mitochondrial outer membrane and the
plasma membrane have found to contribute to autophagosome formation (Hailey et
al, 2010; Ravikumar et al, 2010).
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later, in 1963, de Duve established this research area when he described the term
“autophagy” to describe the presence of single- or double-membrane vesicles that
contain parts of the cytoplasm and organelles in various states of disintegration, at
the Ciba Foundation symposium on lysosomes (de Duve, 1963). In 1966, De Duve
and Wattiaux suggested that the sequestering membranes are derived from preformed
membranes, such as smooth endoplasmic reticulum (de Duve and Wattiaux, 1966).
In 1967, glucagon was found to induce autophagy (Deter et al, 1967). In 1977,
insulin was found to inhibit autophagy (Pfeifer, 1977). In 1982, biochemical analysis
of autophagy was carried out and the pharmacological reagent 3-methyladenine
(3MA) was identified as an autophagy inhibitor (Seglen and Gordon, 1982). In 1992,
the evidence that protein kinase and phosphatase can regulate autophagy was made
known (Holen et al, 1992).
In 1997, Holen and colleagues identified the first autophagy-related gene
Atg1 in Saccharomyces cerevisiae (Matsuura et al, 1997). The morphology of
autophagy in yeast was similar to that documented in mammals (Takeshige et al,
1992). In 1998, the first mammalian autophagy gene was identified, and the Atg12-
Atg5 conjugation system was described (Mizushima et al, 1998). In 2000,
microtubule-associated protein 1 light chain 3 (LC3) detection assays were used for
monitoring autophagy in higher eukaryotes (Kabeya et al, 2000). Three years later, it
was discovered that deficient autophagy contributes to tumorigenesis in vivo (Qu et
al, 2003; Yue et al, 2003).
Autophagy occurs as a housekeeping mechanism in normal growing
conditions (Espert et al, 2007). The functions of autophagy are enabling cell survival
and inducing of damaged cells death (Yousefi and Simon, 2007). Autophagy is
included in several physiological processes involving the response to starvation, cell
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growth control, cell death, differentiation/ development, toxic stimuli and
chemotherapy (Kondo et al, 2005; Kroemer and Jaattela, 2005; Levine and Klionsky,
2004). In addition to the essentiality of autophagy for adaptation and survival during
starvation conditions, autophagy has been shown to play a role in tumor suppression
(Kuma et al, 2004; Qu et al, 2003; Scott et al, 2004; Yue et al, 2003). Decreased
levels of autophagy have been associated with tumor development (Qu et al, 2003;
Yue et al, 2003). The discovery of over 30 Atg genes in yeast has been essential in
the molecular understanding of this process, and many of whose mammalian
orthologues have also been discovered (Espert et al, 2007; Roy and Debnath, 2010).
Autophagy pathway is a multi-step process characterized by induction,
vesicle nucleation, extension and completion of an isolation membrane to form an
organelle called autophagosomes (Roy and Debnath, 2010). The final stages of
autophagy are docking, and fusion with a lysosome, degradation and recycling
(Yoshimori and Noda, 2008). The core autophagy machinery is composed of four
major functional groups: [1] the Atg1-Atg13-Atg17 kinase complex, [2] the, class III
phosphoinositide-3-kinase (PI3K) complex I; including Class III PI3K (the
mammalian orthologue of vascular protein sorting 34; Vps34), p150 (the mammalian
orthologue of Vps15), beclin-1 (the mammalian orthologue of Atg6, also called
Vps30) and Atg14, [3] two ubiquitin-like conjugation systems; Atg12 and Atg8; and
[4] Atg9 and its cycling system (Yang and Klionsky, 2010). A fifth group set of core
components includes protein needed for the last step of autophagy process when the
single-membrane intravascular vesicles and their cargo break down, and permeases
enzymes release these degradation products back into the cytosol for re-use (Epple et
al, 2001; Teter et al, 2001; Yang et al, 2006b). The schematic illustration of
autophagy process is shown in Figure 1.3.
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Figure 1.3 Schematic illustration of autophagy (Yang and Klionsky, 2010).
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Autophagy can be induced by a variety of different stimuli such as nutrient
deprivation, hypoxia, cytokines, etc, and the induction of autophagy is mostly
associated with the mammalian target of rapamycin complex 1 (mTORC1) which is
a central controller of cell growth (Wullschleger et al, 2006). The unc-51-like
kinases (ULKs; the mammalian orthologs of Atg1), which exists in a large complex
with mammalian Atg13 (mAtg13), focal adhesion kinase family interacting protein
of 200 kDa (FIP200; the mammalian homolog of Atg17), and the recently identified
Atg101, played a crucial role in induction of autophagy (Chan et al, 2009; Ganley et
al, 2009; Hara and Mizushima, 2009; Jung et al, 2009; Mercer et al, 2009).
The early stages of nucleation of the phagophore are required to form a class
III PI3K complex which consists of the PI3K class III protein, Beclin-1,and p150
(Simonsen and Tooze, 2009). Recent studies have shown different binding molecules
positively regulate Beclin-1 activity and regulate different steps of autophagosome
formation and maturation, including ultraviolet (UV) radiation resistance-associated
gene (UVRAG), Atg14L, and autophagy/beclin-1 regulator 1 (Ambra1) (Fimia et al,
2007; Itakura et al, 2008; Liang et al, 1999; Matsunaga et al, 2009). The tumor
suppressor, UVRAG, Bax-interacting factor 1 (Bif-1), and probably
Ambra1associated with Beclin-1 to activate autophagy (Takahashi et al, 2007).
The next stage of phagophore membrane elongation requires two ubiquitin-
like systems (Figure 1.4) (Ohsumi and Mizushima, 2004). In the first system of
ubiquitin-like conjugation, the ubiquitin-like protein Atg12 firstly activates by Atg7,
a ubiquitin-activated enzyme (E1)-like protein, and then transfers by Atg10, a
ubiquitin carrier protein (E2)-like protein, to Atg5 through a covalent bond (Gao et
al, 2009). The Atg5-Atg12 complex interacts with Atg16 to form a large multimeric
